Fig. 1.

Sample flow and analysis. (1) 701 samples of breast cancer tumor tissue were obtained from PATH Biobank and analyzed with BEAMing for AKT1 ^E17K. (2) For a sub-cohort (108) of BEAMing-identified AKT1 ^E17K-mutant and wild-type samples, follow-up data were collected and matched serum was ordered. Serum samples were analyzed in a blinded fashion for AKT1 ^E17K (BEAMing). (3) BEAMing-identified AKT1 ^E17K-mutant samples and a sub-cohort of wild-type samples were analyzed by next-generation sequencing. Abbreviations: AKT1 v-akt murine thymoma viral oncogene, BEAMing Beads, Emulsions, Amplification, and Magnetics, FFPE formalin-fixed paraffin-embedded, HER2 human epidermal growth factor receptor 2, PATH, Patients’ Tumor Bank of Hope, PCR polymerase chain reaction, SOP standard operating procedure, UICC Union for International Cancer Control